Evidence map›Paper›PMID 38570849›Full record

ArticleBMC health services research2024

Trends in antidiabetic drug use and expenditure in public hospitals in Northwest China, 2012-21: a case study of Gansu Province.

Wenxuan Cao, Hu Feng, Yaya Yang, Lei Wang, Xuemei Wang, Yongheng Ma, Defang Zhao, Xiaobin Hu

Abstract read
In one paragraph

Article in BMC health services research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenxuan CaoSchool of Public Health, Lanzhou University, 222# Tianshui South Road, Lanzhou, 730000, China.
Hu FengSchool of Public Health, Lanzhou University, 222# Tianshui South Road, Lanzhou, 730000, China.
Yaya YangSchool of Public Health, Lanzhou University, 222# Tianshui South Road, Lanzhou, 730000, China.
Lei WangSchool of Public Health, Lanzhou University, 222# Tianshui South Road, Lanzhou, 730000, China.
Xuemei WangSchool of Public Health, Lanzhou University, 222# Tianshui South Road, Lanzhou, 730000, China.
Yongheng MaDivision of Pharmaceutical Procurement, Gansu Public Resources Trading Center, 68# Yanxing Road, Lanzhou, 730000, China.
Defang ZhaoDivision of Pharmaceutical Procurement, Gansu Public Resources Trading Center, 68# Yanxing Road, Lanzhou, 730000, China.
Xiaobin HuSchool of Public Health, Lanzhou University, 222# Tianshui South Road, Lanzhou, 730000, China. lzhuxb@126.com.

Funding

Research on Total Health Expenditure in Gansu Province 2022620005002671Special Research on Lanzhou University Serving Gansu Economic and Social Development 2019-FWZX-11
6 · The paper itself

Abstract

backgroundSince the twenty-first century, the prevalence of diabetes has risen globally year by year. In Gansu Province, an economically underdeveloped province in northwest China, the cost of drugs for diabetes patients accounted for one-third of their total drug costs. To fundamentally reduce national drug expenditures and the burden of medication on the population, the relevant departments of government have continued to reform and improve drug policies. This study aimed to analyse long-term trends in antidiabetic drug use and expenditure in Gansu Province from 2012 to 2021 and to explore the role of pharmaceutical policy.

methodsData were obtained from the provincial centralised bidding and purchasing (CBP) platform. Drug use was quantified using the anatomical therapeutic chemistry/defined daily dose (ATC/DDD) method and standardised by DDD per 1000 inhabitants per day (DID), and drug expenditure was expressed in terms of the total amount and defined daily cost (DDC). Linear regression was used to analyse the trends and magnitude of drug use and expenditure.

resultsThe overall trend in the use and expenditure of antidiabetic drugs was on the rise, with the use increasing from 1.04 in 2012 to 16.02 DID in 2021 and the expenditure increasing from 48.36 in 2012 to 496.42 million yuan in 2021 (from 7.66 to 76.95 million USD). Some new and expensive drugs changed in the use pattern, and their use and expenditure shares (as the percentage of all antidiabetic drugs) increased from 0 to 11.17% and 11.37%, but insulins and analogues and biguanides remained the most used drug class. The DDC of oral drugs all showed a decreasing trend, but essential medicines (EMs) and medical insurance drugs DDC gradually decreased with increasing use. The price reduction of the bid-winning drugs was over 40%, and the top three drugs were glimepiride 2mg/30, acarbose 50mg/30 and acarbose 100mg/30.

conclusionsThe implementation of pharmaceutical policies has significantly increased drug use and expenditure while reducing drug prices, and the introduction of novel drugs and updated treatment guidelines has led to changes in use patterns.

Indexed as

Diabetes MellitusSubstance-Related DisordersAcarboseChinaDrug CostsHealth ExpendituresHospitals, PublicHumansHypoglycemic AgentsAcarboseHypoglycemic AgentsAntidiabetic drugChinaPharmaceutical policyPublic hospitalsUse pattern

Identifiers

PMID38570849
PMCPMC10988802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.